Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

TC-A Registration Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02139345
Recruitment Status : Completed
First Posted : May 15, 2014
Last Update Posted : November 14, 2017
Sponsor:
Information provided by (Responsible Party):
Smith & Nephew Medical (Shanghai) Ltd

Brief Summary:
This is a prospective, randomized, multicenter clinical study to compare the safety and efficacy of TC-A PS total knee system with TC-PLUS Solution PS total knee system in Chinese subjects.

Condition or disease Intervention/treatment Phase
Primary Osteoarthritis Rheumatoid Arthritis Post-traumatic Arthritis Avascular Necrosis Device: TC-A PS Total Knee Replacement System Device: TC-PLUS Solution PS Total Knee Replacement System Not Applicable

Detailed Description:

Osteoarthritis (OA), also known as degenerative joint disease or hyperostosis, is the most common cause of knee arthritis. Pain, dyskinesia and disability induced by osteoarthritis impact severely on the subject's health and quality of life. Knee osteoarthritis is very common in the elderly population. As life expectancy has increased, the incidence of osteoarthritis rose significantly during the 20th century. For people over 60 years of age, approximately 50% show signs of osteoarthritis on x-rays, among which 35% -50% show clinical signs. For people over the age of 75, 80% had osteoarthritis symptoms.

There has been an increase in imported knee prostheses during the past decade, so that surgeons now have more choices of implants. However, the high cost of imported prostheses has become a barrier to the development of TKA in China and caused many OA subjects requiring immediate TKA to have to delay or miss their surgery. The development and promotion of high-quality domestic joint implants and surgical instruments is the key to the development of TKA technique in China.

The primary objective of this study is to demonstrate non-inferiority of subjects implanted with the TC-A PS total knee system compared to a randomized concurrent control group of subjects implanted with the TC-PLUS Solution PS total knee system in terms of Knee Society Clinical Score (KSCS) at 1 year.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 162 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subject was randomized to receive the treatment of investigational device or the comparator.
Masking: Single (Outcomes Assessor)
Masking Description: Investigator who assesses KSS score is blinded to the subject's treatment.
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Multicenter Clinical Study to Compare the Safety and Efficacy of TC-A PS Total Knee System With TC-PLUS Solution PS Total Knee System in Chinese Subjects
Actual Study Start Date : September 23, 2014
Actual Primary Completion Date : November 23, 2016
Actual Study Completion Date : November 23, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TC-A PS
Subject will be implanted with the TC-A PS Total Knee Replacement System
Device: TC-A PS Total Knee Replacement System
Subject will be implanted with the TC-A PS Total Knee Replacement System
Other Name: TC-A PS

Active Comparator: TC-PLUS Solution PS
Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System.
Device: TC-PLUS Solution PS Total Knee Replacement System
Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System
Other Name: TC-PLUS Solution PS




Primary Outcome Measures :
  1. The Original Knee Society Clinical Score (KSCS) [ Time Frame: 1 year post-operative ]
    The Knee Society Clinical Score (KSCS) - points are given for pain, motion, and stability and points are deducted for flexion contracture, extension lag, and misalignment. For the results, a score of 80-100 = excellent, 70-79 = good; 60-69 = fair; and < 60 = poor.


Secondary Outcome Measures :
  1. The Original Knee Society Functional Score (KSFS) [ Time Frame: 1 year post-operative ]
    The Knee Functional Score (KSFS) - points are assigned for walking distances and climbing stairs and points are deducted for use of walking aids. For the result, a score of 80-100 = excellent, 70-79 = good; 60-69 = fair; and < 60 = poor.

  2. Revision for any reason [ Time Frame: Up to 1 year post-operative ]
    Revision for any reason will be assessed and documented up to 1 year post-operative.

  3. Linear radiolucencies and radiographic abnormalities [ Time Frame: Up to 1 year post-operative ]
    Radiographic measurements will be taken of linear radiolucencies and the radiographs will be evaluated for any abnormalities.

  4. Western Ontario and McMaster Universities Arthritis Index (WOMAC) [ Time Frame: 1 year post-operative ]

    The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a widely used, proprietary set of standardized questionnaires used by health professionals to evaluate the condition of subjects with osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning of the joints.

    The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). Physical functioning questions cover everyday activities such as stair use, standing up from a sitting or lying position, standing, bending, walking, getting in and out of a car, shopping, putting on or taking off socks, lying in bed, getting in or out of a bath, sitting, and heavy and light household duties.


  5. SF-12 Health Survey [ Time Frame: 1 year post-operative ]
    The SF-12 Health Survey was first developed in 1995 as a shorter version of the SF-36 Health Survey used for measuring the overall health condition of the general population. The usefulness of SF-12 is improved by its simplicity and less time needed for completion, and it has a good reliability on the evaluation of quality of life. The SF-12v2 Health Survey is a 12-item generic Health-Related Quality of Life measure consisted of eight subscales: Physical functioning (PF), Role physical (RP), Bodily pain (BP), General health (GH), Vitality (VT), Social functioning (SF), Role emotional (RE) and Mental health (MH); and two composite summary scores: Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. All subscales and summary scores were ranged from 0-100. The higher the SF-12 score, the better the HRQOL outcome.

  6. Number of subjects with adverse events [ Time Frame: Up to 1 year post-operative ]
    Safety will be evaluated by collecting the frequency and nature of all postoperative adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects, aged between 50 and 75 years inclusive of Chinese ethnicity.
  • Subject presents with primary osteoarthritis, rheumatoid arthritis, post-traumatic arthritis or avascular necrosis of knee joint requiring primary total knee replacement with the PS knee system.
  • Subject who is able to give voluntary, written informed consent to participate in the study and from whom consent has been obtained by signing and dating an EC-approved consent form.
  • Subject who is able to understand this clinical study, co-operates with the investigational procedures and is willing to return to the hospital for all the required post-operative follow-ups for up to 12 months.
  • Life expectancy of subject is over 2 years.

Exclusion Criteria:

  • Bilateral knee disease with the anticipated need for bilateral knee implant during study participation (i.e., within the next 12 months).
  • Subject has known or suspected metal sensitivity.
  • Subject is known to have insufficient femoral or tibial bone stock resulting from conditions such as cancer, distal femoral/proximal tibial osteotomy, significant osteoporosis or metabolic bone disorders, which cannot provide adequate support and/or fixation to the prosthesis.
  • Subject is severely obese (BMI>35).
  • Subject has hip arthritis and/or replacement.
  • Subject had an active infection or sepsis (treated or untreated)
  • Subject has conditions that may compromise implant stability or postoperative recovery (i.e., Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease).
  • Subject has an emotional or neurological condition that would affect their ability or willingness to participate in the study (e.g. mental illness, mental retardation).
  • Subject is immunosuppressed, has an autoimmune disorder, or an immunosuppressive disorder. For examples, subject is on immunosuppressive therapy (corticosteroid hormones in large amounts, cytotoxic drugs, antilymphocytic serum or irradiation in large doses) or has acquired immunodeficiency syndrome (AIDS).
  • Subject is a woman who is pregnant or lactating,or intends to become pregnant during the course of the study.
  • Subject is known to be at risk for lost to follow-up, or failure to return for scheduled visits.
  • Subject was enrolled in another investigational drug, biologic, or device study in the last 12 months.
  • Known alcohol and/or drug abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02139345


Locations
Layout table for location information
China, Jiangsu
Nanjing First Hospital
Nanjing, Jiangsu, China, 100730
China, Jilin
The First Hospital of Jilin University
Changchun, Jilin, China, 100035
China, Xinjiang
The First Teaching Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China, 830054
China
Peking University People's Hospital
Beijing, China, 100044
Sponsors and Collaborators
Smith & Nephew Medical (Shanghai) Ltd
Investigators
Layout table for investigator information
Principal Investigator: Jianhao Lin, Professor Peking University People's Hospital
Layout table for additonal information
Responsible Party: Smith & Nephew Medical (Shanghai) Ltd
ClinicalTrials.gov Identifier: NCT02139345    
Other Study ID Numbers: 13-4060-04
First Posted: May 15, 2014    Key Record Dates
Last Update Posted: November 14, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Smith & Nephew Medical (Shanghai) Ltd:
Osteoarthritis
Rheumatoid arthritis
Post-traumatic arthritis
Avascular necrosis
AVN
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Osteoarthritis
Arthritis, Rheumatoid
Necrosis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Pharmaceutical Solutions